Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
839.5 DKK | +0.71% | +2.59% | +8.73% |
Jun. 06 | Transcript : Coloplast A/S - Analyst/Investor Day | |
May. 15 | COLOPLAST : Multiple silver linings in spite of a soft Q2 24 |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.94 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.73% | 26.99B | B+ | ||
-41.92% | 2.63B | B- | ||
+25.19% | 2.44B | B | ||
-23.19% | 2.31B | C+ | ||
+5.99% | 2.21B | - | A- | |
+22.22% | 1.87B | B | ||
+32.97% | 1.33B | C | ||
+30.58% | 1.37B | B | ||
+0.25% | 1.3B | - | ||
+32.62% | 1.02B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- COLO B Stock
- Ratings Coloplast A/S